Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab
Open Access
- 5 November 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (1) , e212-e220
Abstract
Background: High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30 mg/kg) and zinlirvimab (10 or 30 mg/kg), in virologically suppressed people with HIV-1 susceptible (IC90 ≤ 2 μg/mL) to both (primary cohort, n = 20) or either (pilot cohort, n = 10) bNAb. We describe resistance analyses through Week (W) 26. Methods: Post-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. Low copy number genotyping methods for capsid and a 1 kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed. Results: Virologic failure was observed in 1/30 participants. This primary cohort participant had HIV RNA 155 copies/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, experienced virologic rebound at W26 (55 and 72 copies/mL) and restarted oral antiretrovirals. In exploratory analyses, neither had emergent lenacapavir resistance or altered bNAb susceptibility. Conclusions: Lenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.Keywords
Funding Information
- Gilead Sciences, Inc.
This publication has 42 references indexed in Scilit:
- Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical IsolatesJournal of Medical Virology, 2025
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyThe Lancet HIV, 2024
- Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialThe Lancet HIV, 2022
- Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing AntibodyCell, 2020
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine DesignCell Host & Microbe, 2019
- Combination therapy with anti-HIV-1 antibodies maintains viral suppressionNature, 2018
- Antibody 10-1074 suppresses viremia in HIV-1-infected individualsNature Medicine, 2017
- HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionNature, 2016
- Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Nature, 2015
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virusNature, 2013